Comparison
Coenzyme Q10 vs Omega-3 (EPA/DHA)
Side-by-side of Coenzyme Q10 and Omega-3 (EPA/DHA). Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Coenzyme Q10
CoQ10 supplement guide: 100 to 300 mg/day dosing, ubiquinol vs ubiquinone absorption, Q-SYMBIO heart failure data, statin myalgia evidence.
Omega-3 (EPA/DHA)
Omega 3 fish oil profile: EPA/DHA marine fatty acids, 2-4 g/day cuts triglycerides 20-30%, REDUCE-IT showed 25% cardiovascular risk reduction on icosapent eth.
Effects at a glance
Coenzyme Q10
- •Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- •Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- •Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- •Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- •Plasma CoQ10 falls 15-40% with chronic statin therapy
- •Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
Omega-3 (EPA/DHA)
- •Reduces fasting triglycerides 20-50% at 2-4 g/day in hypertriglyceridemic patients
- •REDUCE-IT showed 25% relative risk reduction in major CV events at 4 g/day icosapent ethyl
- •Modest antidepressant effect (SMD ~0.40) for EPA-dominant formulations at 1-2 g/day
- •Atrial fibrillation incidence rises ~30-50% at 4 g/day; relevant for older patients with pre-existing CV disease
- •Tissue omega-3 index (RBC EPA + DHA) target ~8%; Western baseline typically 4-5%
- •Triglyceride and re-esterified triglyceride forms absorb ~70% better than ethyl esters in fasted state
Side-by-side
| Attribute | Coenzyme Q10 | Omega-3 (EPA/DHA) |
|---|---|---|
| Category | supplement | supplement |
| Also known as | CoQ10, ubiquinone, ubiquinol, Q10 | fish oil, EPA, DHA, marine omega-3 |
| Half-life (hr) ↗ | 34 | 48 |
| Typical dose (mg) ↗ | 200 | 2000 |
| Dosing frequency | 1 to 3 times daily with a fat-containing meal | 1 to 2 times daily with food |
| Routes | oral | oral |
| Onset (hr) | 6 | 4 |
| Peak (hr) | 720 | 12 |
| Molecular weight | 863.36 | 302.45 |
| Molecular formula | C59H90O4 | C20H30O2 (EPA); C22H32O2 (DHA) |
| Mechanism | Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E. | Substitutes arachidonic acid in membrane phospholipids, shifting eicosanoid production toward less-inflammatory 3-series prostaglandins and 5-series leukotrienes. Activates PPAR-alpha to lower hepatic VLDL/triglyceride synthesis. DHA modulates synaptic membrane fluidity and neuronal function. |
| Legal status | Dietary supplement (most jurisdictions); prescription cardiac medication in Japan | Dietary supplement; prescription forms (icosapent ethyl, omega-3 acid ethyl esters) for severe hypertriglyceridemia |
| WADA status | allowed | allowed |
| DEA / Rx | Not scheduled | Not scheduled |
| Pregnancy | Limited safety data; precautionary use at standard doses | Recommended at 200 to 600 mg DHA/day for fetal development |
| CAS | 303-98-0 | 10417-94-4 |
| PubChem CID | 5281915 | 446284 |
| Wikidata | Q140453 | Q207688 |
Safety profile
Coenzyme Q10
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Contraindications
- active warfarin therapy without monitoring (modest interaction with INR)
Interactions
- warfarin: structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR(moderate)
- antihypertensives: additive blood pressure-lowering at high doses(minor)
- statins: statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy(minor)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Omega-3 (EPA/DHA)
Common side effects
- fishy aftertaste
- eructation (fish burps)
- mild dyspepsia
- loose stools at high doses
Contraindications
- fish allergy (use algal omega-3 alternative)
- active bleeding disorders
- scheduled surgery (discontinue 5-7 days prior)
Interactions
- warfarin and DOACs: additive antiplatelet effect at 2+ g/day; meaningful bleeding risk(moderate)
- aspirin and antiplatelet agents: additive bleeding risk at high doses(moderate)
- statins: complementary cardiovascular effects; no pharmacokinetic interaction(minor)
- antiarrhythmics: high-dose omega-3 increases AF risk; relevant in pre-existing arrhythmia(moderate)
Which Should You Take?
Coenzyme Q10 and Omega-3 (EPA/DHA) score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is energy and stamina, pick Coenzyme Q10.
- → If your priority is focus or working memory, pick Omega-3 (EPA/DHA).
- → If your priority is cardiovascular health, pick Coenzyme Q10.
Default choice: either is defensible. Coenzyme Q10 edges out on goal breadth + legal accessibility; Omega-3 (EPA/DHA) is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Coenzyme Q10 and Omega-3 (EPA/DHA)?
Coenzyme Q10 and Omega-3 (EPA/DHA) differ in category (supplement vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Coenzyme Q10 or Omega-3 (EPA/DHA)?
Coenzyme Q10 half-life is 34 hours; Omega-3 (EPA/DHA) half-life is 48 hours.
Can you stack Coenzyme Q10 with Omega-3 (EPA/DHA)?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper